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Abstract
Background: Esophageal squamous cell carcinoma (ESCC) is one of the most malignant tumors and
typically presents at an advanced and rapidly fatal stage. To better understand the role of genetics in the
etiology and prevention of ESCC and to identify potential susceptibility genes as well as early detection
markers, we previously compared tumor and matched normal tissues from ESCC patients from a high-risk
area of China using cDNA expression microarrays and identified 41 differentially-expressed genes (13
over-expressed and 28 under-expressed).
Methods: In the current study, we validated and quantitated differential mRNA expression in a sample of
nine of these 41 genes, including four that were over-expressed (SPARC, FADD, Fascin, COL7A1), and five
that were under-expressed (CK4, TGM3, ECM1, PPL, EVPL), in 75 new ESCC patients using quantitative
Real-time RT-PCR and the 2-∆∆CT method to examine both tumor and matched normal tissue. In addition,
we examined expression patterns for these genes by selected demographic and clinical characteristics.
Results: Four previously over-expressed (tumor ≥2-fold normal) genes were all increased in the majority
of new ESCC patients: SPARC was increased in 71% of patients, Fascin in 70%, FADD in 63%, and COL7A1
in 57%. Five previously under-expressed (tumor ≤0.5-fold normal) genes similarly showed decreased
mRNA expression in two-thirds or more of patients: CK4 was decreased in 83% of patients, TGM3 in 77%,
ECM1 in 73%, and PPL and EVPL in 67% each. In subset analyses, associations with age (for COL7A1), family
history (for PPL and ECM1), and alcohol use (for SPARC and Fascin) were also noted.
Conclusion: These data indicate that these nine genes have consistent differential mRNA expression,
validating results of our previous cDNA array results, and affirming their potential role in the early
detection of ESCC.
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Background
Esophageal squamous cell carcinoma (ESCC) is one of the
most malignant tumors and typically presents at an
advanced and rapidly fatal stage. To better understand the
role of genetics in the etiology and prevention of ESCC
and to identify potential susceptibility genes as well as
early detection markers, we previously compared tumor
and matched normal tissues from ESCC patients from a
high-risk area of China using cDNA expression microar-
rays and identified 41 differentially-expressed genes (13
over-expressed and 28 under-expressed) [1].
Among these 41 differentially-expressed genes are SPARC
(secreted protein acidic and rich in cysteine), COL7A1
(collagen type VII, α), and ECM1  (extracellular matrix
protein), all of which are involved in extracellular matrix
functions [2-4]. Other of these differentially-expressed
genes (eg, Fascin and cytokeratin 4, also called KRT4 or
CK4) are involved in the formation of actin filaments and
cytoskeleton structure [5,6].PPL  (periplakin) and EVPL
(enveloplakin) are both members of the plakin family [7-
9]. PPL is expressed in stratified squamous epithelia while
EVPL, a candidate gene for the tylosis esophageal cancer
syndrome, is exclusively expressed in stratified squamous
epithelia. Both PPL and EVPL have desmosome compo-
nents and, in conjunction with TGM3 (transglutaminase)
and cystatin A, they help to maintain an intact cell surface
interface [10,11]. FADD (Fas-associated death domain)
interacts with FasL and Caspase-8 to initiate the Fas signal-
ing complex which leads to apoptosis [12]. All nine of
these genes identified in our previous study [1] are
involved in important cellular processes, and their altered
expression in ESCC suggests that they are candidate
molecular markers that may have a role in prevention and
early detection strategies in ESCC.
Array technologies are comprehensive and relatively accu-
rate ways to simultaneously analyze the expression of
thousands of genes, and these technologies have been
used to clarify gene expression changes in many human
malignancies. However, the results from microarrays are
potentially influenced by many external factors, including
array production itself, RNA extraction methods, the
probes used for labeling, hybridization conditions, image
analysis, etc. Further, most studies of this type are based
on relatively small sample sizes, including our study [1].
Thus, genes identified as differentially expressed in such
initial discovery efforts need to be confirmed using alter-
native methods and larger sample sizes before they can be
considered validated and advanced for testing as early
detection markers. This confirmation is a key initial step
in the validation process for selecting genes for future
study as potential markers of susceptibility or early dis-
ease.
The main goal of the current study was to validate the dif-
ferential mRNA expression of nine selected genes (SPARC,
FADD,  Fascin,  COL7A1,  CK4,  TGM3,  ECM1,  PPL  and
EVPL) in a relatively large sample of ESCC cases using
quantitative Real-time RT-PCR. A secondary goal was to
determine if expression patterns for these nine genes var-
ied by selected demographic and clinical characteristics.
Methods
Patient selection and sample collection
This study was approved by the Institutional Review
Boards of the Shanxi Cancer Hospital and the U.S
National Cancer Institute (NCI). Patients presenting from
1996 to 2001 to the Shanxi Cancer Hospital in Taiyuan,
Shanxi Province, People's Republic of China, who were
diagnosed with ESCC and considered candidates for cura-
tive surgical resection were identified and recruited to par-
ticipate in the study. None of the patients had prior
therapy and Shanxi was the ancestral home for all. After
obtaining informed consent, patients were interviewed to
obtain information on demographic and lifestyle cancer
risk factors (eg, smoking, alcohol drinking, family history
(FH) of upper gastrointestinal (UGI) cancer) and clinical
data. Tumor tissue obtained during surgery was snap-fro-
zen in liquid nitrogen, along with matched normal tissue,
and stored at -130 C until used. The 75 patients evaluated
here were selected based on the quantity and quality of
their total RNA from among 110 who had sufficient
tumor and matched normal tissues.
Real-time quantitative RT-PCR
Total RNA was extracted from frozen tumor and matched
normal tissues using TRIzol reagent (Invitrogen, CA, USA)
in accordance with the manufacturer's instructions. RNA
quality and quantity were determined using the RNA
6000 Labchip/Agilent 2100 Bioanalyzer (Agilent Technol-
ogies, Germantown, MD). RNA purification was per-
formed according to the manufacturer's instructions for
the RNeasy Mini Kit (Qiagen Inc., Valencia, CA) and
Rnase-Free Dnase Set digestion (Qiagen Inc., Valencia,
CA). Reverse transcription of RNA was performed by add-
ing 5 µg total RNA, 1 µl of Oligo (dT)12–18 (500 µg/ml), 1
µl (200 units) of Superscript II reverse transcriptase, 1 µl
(2 units) of E. coli Rnase, and 1 µl 10 mM dNTP (Invitro-
gen, Carlsbad, CA).
All real-time PCR reactions were performed using an ABI
Prism 7000 Sequence Detection System (Perkin-Elmer
Applied Biosystems, Foster City, CA). All primers and
probes of nine target genes and an internal control gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
were designed by Perkin-Elmer Applied Biosystems Per-
kin-Elmer Applied Biosystems, Foster City, CA) (Table 1).
A singleplex reaction mix was prepared according to the
manufacture's protocol, as described previously [13]. TheBMC Cancer 2006, 6:33 http://www.biomedcentral.com/1471-2407/6/33
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thermal cycling conditions included an initial denatura-
tion step at 95°C for 10 min, 40 cycles at 95°C for 15 s,
and 60°C for one min.
Using these quantitative methods requires that the PCR
efficiencies of all genes be similar and, preferably, ≥90%.
Efficiency was measured using a standard curve generated
by serial dilutions of the RNA. Consequently, the initial
RNA concentration of 100 ng/µl was serially diluted 10-
fold (100 ng, 10 ng, 1 ng, 0.1 ng, and 0.01 ng) for the real-
time PCR assay according to the standard protocol of
Applied Biosystems. The relative standard curve quantita-
tion method was previously described [14]. The PCR effi-
ciency (E) was calculated by the formula: E = 10 (1/-slope) -
1, and ranged from 90–100% in the different assays (a
slope of -3.32 is equivalent to 100% PCR efficiency)
[14,15].
Analysis of gene expression using the 2-∆∆CT method
Details of the 2-∆∆CT  method have been previously
described [14,16]. Briefly, the mean target gene mRNA
expression level for the three mRNA measurements was
calculated. The 2-∆∆CT method was used to calculate rela-
tive changes in gene expression determined from real-
time quantitative PCR experiments. In the present study,
the data are presented as the fold change in target gene
expression in tumors normalized to the internal control
gene (GAPDH) and relative to the normal tissue control
(matched normal as calibrator). Results of the real-time
PCR data were represented as CT values, where CT was
defined as the threshold cycle number of PCRs at which
amplified product was first detected. There is an inverse
correlation between CT  and amount of target: lower
amounts of target correspond to a higher CT value, and
higher amounts of target have lower CT values. The aver-
Table 1: Information on the nine genes examined: location, function, primers and probes
No Gene LocusLink Location Putative function Catalogue number for primer & probe (ABI)
1 SPARC 6678 5q31.3-q32 Extracellular matrix remodeling Hs00277762-m1
2 FADD 8772 11q13.3 Death receptor/cytoplasmic response Hs00538709-m1
3 Fascin 6624 7p22 Cytoskeleton/regulation of cellular Hs00979629-g1
4 COL7A1 1294 3p21.1 Extracellular matrix Hs00164310-m1
5 CK4 3851 12q12-q13 Cytoskeleton Hs00361611-m1
6 TGM3 7053 20q11.2 Protein modification Hs00162752-m1
7 ECM1 1893 1q21 Extracellular matrix Hs00189435-m1
8 PPL 5493 16p13.3 Cytoskeleton Hs00160312-m1
9 EVPL 2125 17q25 Epidermal differentiation and maintenance Hs00157430-m1
10 GAPDH Hs99999905-m1
Table 2: Demographic and clinical characteristics of ESCC patients (N = 75)
Characteristic Males (N = 42) Females (N = 33) All (N = 75)
Age (median) 57 yrs 55 yrs 56 yrs
Tumor location
Lower 10 (24%) 4 (12%) 14 (19%)
Middle 30 (71%) 27 (82%) 57 (76%)
Upper 2 (5%) 2 (6%) 4 (5%)
Tumor grade
I 4 (10%) 2 (6%) 6 (8%)
II 28 (67%) 23 (70%) 51 (68%)
III 10 (24%) 8 (24%) 18 (24%)
Tumor stage
1 1 (2%) 0 (0%) 1 (1%)
2 7 (17%) 6 (18%) 13 17%)
3 33 (79%) 27 (82%) 60 (80%)
4 1 (2%) 0 (0%) 1 (1%)
Metastases (yes) 19 (45%) 15 (45%) 34 (45%)
Family history of UGI* cancer (yes) 12 (29%) 11 (33%) 23 (31%)
Tobacco use (yes) 34 (81%) 5 (15%) 39 (52%)
Alcohol drinking (yes) 10 (24%) 0 (0%) 10 (13%)
*Upper gastrointestinalBMC Cancer 2006, 6:33 http://www.biomedcentral.com/1471-2407/6/33
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age CT  was calculated for both the target genes and
GAPDH and the ∆CT was determined as (the mean of the
triplicate CT values for the target gene) minus (the mean of
the triplicate CT values for GAPDH). The ∆∆CT represented
the difference between the paired tissue samples, as calcu-
lated by the formula ∆∆CT = (∆CT of tumor - ∆CT of nor-
mal). The N-fold differential expression in the target gene
of a tumor sample compared to the normal sample coun-
terpart was expressed as 2-∆∆CT [14,16]. In the present
study, increased mRNA expression was defined as N-fold
≥2.0, "normal" expression was an N-fold ranging from
0.5001 to 1.9999, and decreased mRNA expression was
N-fold ≤0.5.
Data analysis
Hierarchical cluster analysis and visualization were gener-
ated by Cluster and TreeView software [17].
The associations between mRNA expression level of target
genes and life style risk factors as well as clinical/patholog-
ical characteristics listed in Table 2 were evaluated by
using chi-square tests for analysis of categorical variables
and Wilcoxon rank sum tests for analysis of continuous
variables (Statistical Analysis Systems (SAS), SAS Corp.,
NC). All P-values were two-sided and considered statisti-
cally significant if P < 0.05.
Results
A total of 75 pairs of tumor and matched normal tissues
from ESCC patients were examined for mRNA expression
of nine genes using quantitative Real-time RT-PCR. Table
2 shows the characteristics of patients in the present study.
The PCR efficiency (E) for the nine genes was measured
using standard curves generated by serial dilutions of RNA
and ranged from 90% to 100% for the nine genes tested
(Table 1 and Fig 1). Quantitative RT-PCR analyses of
mRNA levels were performed using paired normal-tumor
mRNA extracts and the 2∆∆CT method. The mRNA expres-
sion values for all 75 ESCC patients tested are shown in
Fig 2 and Fig 3 and summarized in Table 3. Briefly, all four
genes over-expressed in our initial study also had
increased mRNA expression (≥2-fold in tumor versus nor-
mal) in the majority of the new ESCC patients tested
(shown in red in Fig 2): SPARC was increased in 71% of
cases, Fascin in 70%, FADD in 63%, and COL7A1 in 57%.
Likewise, the five genes previously identified in our initial
cDNA study as under-expressed (≤0.5-fold in tumor ver-
sus normal) also had decreased mRNA expression in two-
thirds or more of the new patients examined (shown in
green in Fig 2): CK4 was decreased in 83% of cases, TGM3
in 77%, ECM1 in 73%, and PPL and EVPL decreased in
67% each. Overall, the results of the current study indicate
a reasonably consistent pattern for mRNA expression in
these nine genes in ESCC patients (Table 3), and are quite
compatible with the findings of our earlier cDNA micro-
array study [1].
The range of mRNA expression found using the quantita-
tive real-time RT-PCR method was very broad (Table 3).
Among the nine genes, TGM3 had the greatest range of
mRNA expression (from 0.000 to 35857-fold difference),
while PPL had the smallest range (0.0076 to 29.9953-fold
difference). Several ESCC cases had unusually different
mRNA expression patterns for a few genes. These outliers
had not only opposite expression pattern, but also had
extremely low (<0.01-fold) or high mRNA expression
level (>100-fold change). For example, 70% of cases had
increased mRNA expression for Fascin, but SHE1233 and
SHE1338 had very low Fascin mRNA expression (0.0033
and 0.0091-fold change, respectively). In addition, most
cases had decreased ECM1, TGM3 and EVPL mRNA
expression, but SHE1992 had increased mRNA expression
for ECM1 and TGM3 (139- and 1050-fold changes,
respectively), SHE1289 had extremely high mRNA expres-
sion for TGM3 (35857-fold) and CK4 (467-fold change),
and SHE1432 had increased mRNA expression for EVPL
(136-fold change) and TGM3 (99-fold change). This phe-
nomenon regarding extreme variation in mRNA expres-
sion strongly suggests that there is heterogeneity in ESCC,
even when all the patients studied come from a geograph-
ically similar high-risk population [18].
We also explored the relationships between mRNA
expression levels for each target gene and age, gender,
The relative standard curve using the TGM3 gene, primers,  and probes amplified with 100, 10, 1, 0.01 ng of total RNA Figure 1
The relative standard curve using the TGM3 gene, primers, 
and probes amplified with 100, 10, 1, 0.1 and 0.01 ng of total 
RNA. Each sample was run in triplicate (red square). The 
average CT values (y-axis) are plotted against the logarithm of 
the input amount of RNA (x-axis) added to each sample. 
PCR efficiency (E) = (10-1/slop - 1). It shows a linear relation-
ship between RNA concentration and the CT value of 
reverse transcription real-time PCR reaction for TGM3.
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smoking, alcohol drinking, FH of UGI cancer, and the
four clinical characteristics listed in Table 2 and identified
five potential associations using the nominal P-value cut-
off of 0.05. Family history of UGI cancer has been of par-
ticular interest to us since we previously showed that FH
(+) cases had greater allelic loss than FH (-) cases [19,20]
and that gene expression profiles varied by FH status [1].
As a result, we examined expression of all nine genes by
FH status in this study (Table 4). Two genes, PPL and
ECM1, had lower mRNA expression in FH (+) ESCC cases
than in FH (-) cases (78% versus 62% under-expression,
respectively, for PPL, Wilcoxon rank sum test P = 0.040;
and 87% versus 67% under-expression, respectively, for
ECM1, Wilcoxon rank sum test P = 0.038). Expression of
two other genes, TGM3 and EVPL, showed lower median
values in FH (+) versus FH (-) cases, although the results
did not achieve statistical significance (0.05 <P < 0.10 for
both). Interestingly, the median values for all nine genes
were universally more extreme in FH (+) than FH (-) cases
(ie, the five under-expressed were more under-expressed
in FH (+) cases; the four over-expressed were more over-
expressed in FH (+) cases). Older age was associated with
over-expression of COL7A1 (63% over-expression in cases
56+ years of age versus 50% over-expression in cases <56
years old, Wilcoxon rank sum test P = 0.030). Alcohol use
was associated with reduced over-expression of both
SPARC  and  Fascin  (over-expression of 40% in alcohol
users versus 75% in non-users for SPARC, χ2
2 df = 8.38, P
= 0.015; over-expression of 50% in alcohol users versus
74% in non-users for Fascin, χ2
2 df = 13.15, P = 0.001). No
other significant associations were found for these varia-
bles.
Discussion
Our interest in further validation of initial results from
DNA microarray technology and quantitation of measure-
ments to better understand the nature of differences led us
to perform quantitative Real-time RT-PCR analyses of
nine of the differentially expressed genes we identified in
a previous study [1]. Reassuringly, results from the current
study show that the differential expression patterns for
these nine genes are similar to those seen with the 8 k
cDNA array [1]. Four genes that were over-expressed in
our first study (SPARC, FADD, Fascin, and COL7A1) also
showed increased mRNA expression in the majority of the
new ESCC patients tested here, while five genes previously
under-expressed (CK4,  TGM3,  ECM1,  PPL, and EVPL)
were also under-expressed in two-thirds or more of new
cases. Taken together, the results from these two studies
indicate that the differential expression observed is highly
consistent.
The mRNA expressions of the nine genes examined had
wide ranges, suggesting that quantitative Real-time RT-
PCR is a highly sensitive method, with demonstrable abil-
ity to detect mRNA expression differences from less than
0.01-fold to more than 100-fold. If a normal range can be
established from non-diseased subjects, this apparent
high degree of precision should prove useful for accu-
rately discriminating patient values in the future in both
early detection and treatment evaluation settings.
The mRNA expression of nine genes in 75 ESCC patients  using hierarchical cluster with the average linkage uncentered  correlation method Figure 2
The mRNA expression of nine genes in 75 ESCC patients 
using hierarchical cluster with the average linkage uncentered 
correlation method. The cases with increased mRNA 
expression are shown in red; cases with decreased mRNA 
expression are in shown in green.BMC Cancer 2006, 6:33 http://www.biomedcentral.com/1471-2407/6/33
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Selection of a housekeeping gene as an internal control is
a key issue when RT-PCR is used to study mRNA expres-
sion [21]. In the present study, we selected GAPDH as an
internal control. While mRNA expression of GAPDH may
not be the same in different tissues [21], we believe that it
was a satisfactory control gene for the present study
because both tumor and matched normal esophageal tis-
sues were used and the values for tumor and normal were
both normalized to GAPDH as an initial step in the data
analysis.
SPARC protein is a non-structural component of extracel-
lular matrix-associated matricellular glycoprotein. It is
known that SPARC protein is involved in the formation of
focal adhesions and cytoskeletal structure, and that differ-
ent levels influence cell adherence and migration capacity,
potentially playing a role in the invasion and metastasis of
tumor.  SPARC  has previously been shown to have
increased mRNA expression in various human cancers,
including ESCC, where it has been studied using array
technology [22,23]. In the present study, we found
increased mRNA expression of SPARC in 71% of patients.
Yamahita et al also found high expression of SPARC
mRNA in all 48 ESCC patients examined using Northern
blot hybridization [24]. In another study, SPARC mRNA
expression using the RT-PCR method was lowest in nor-
mal esophagus, intermediate in Barrett's esophagus, and
highest in esophageal adenocarcinoma [25]. SPARC pro-
tein can be measured in human serum [26], thus, future
study of the role of SPARC in ESCC should consider com-
parison of serum levels in cases and controls as an early
step in assessing the potential value of SPARC protein as a
biomarker for early detection or screening in a high-risk
populations. Taken together, these results suggest that
The distribution of mRNA expression of nine genes in 75 ESCC patients Figure 3
The distribution of mRNA expression of nine genes in 75 ESCC patients. Increased expression (≥2 N-fold) is shown in red; 
"normal" expression (N-fold from 0.50001 to 1.9999) is shown in yellow; decreased expression (N-fold ≤0.5) is shown in 
green.
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SPARC plays an important role in esophageal carcinogen-
esis and merits further investigation to determine how
early in this process it becomes dysregulated.
Fascin is the first of the fascins to be cloned and is a highly
conserved 55-KD actin-bundling protein. Fascin functions
in the organization of two major forms of actin-based
structures: dynamic cortical cell protrusions, and cytoplas-
mic microfilament bundles (eg, filopodia, spikes, lamel-
lipodial ribs, dendrites and microvilli) [27]. The
expression of fascin  in epithelial neoplasms has been
described only recently. In normal epithelial cells, fascin
expression is usually absent or very low, but is often up-
regulated in several types of human cancers, such as colon
[28], breast [29], lung [30], and gastric [31]. To date, it has
not been reported in ESCC. In a pilot study, we procured
normal epithelia, dysplasia, and tumor from each of 11
esophagectomized ESCC patients and examined fascin
protein expression by immunohistochemistry. Staining
was strongest in tumor, intermediate in dysplasia, and
absent in normal epithelia (unpublished data). These
results suggest that the mRNA and protein expression pat-
terns for fascin are similar, and that fascin could be a useful
biomarker in ESCC patients.
CK4, a type II keratin, is typically paired with CK13 in
expression in non-keratinized stratified epithelia of the
upper digestive tract. Mutation of the CK4 gene can cause
White Sponge Nevus, a benign autosomal dominant dis-
order that presents as leukokeratosis, usually in the
mouth, but has also been reported in the esophagus and
anogenital mucosa [32]. While CK4 protein alteration has
been observed in many upper digestive tract tumors,
including adenocarcinoma of the esophagus [33], it has
not previously been reported in ESCC. In another pilot
study, we found that CK4 protein expression, compared
to normal epithelia, was decreased in 80% of dysplastic
epithelia and 85% of invasive tumors (unpublished data).
The reason CK4  expression is decreased in ESCC is
unclear, but decreased expression of CK4 does influence
the formation of cytoskeletal cells and this change may
play a role in the development of tumor.
EVPL, PPL, and TGM are all involved in stabilizing the
cornified cell envelope and, like CK4  discussed above,
were all under-expressed in the ESCC patients evaluated
in this study. Other investigators have shown that the C-
terminus of PPL plays an important role in linking PPL
and EVPL to intermediate filaments [34]. EVPL is a candi-
date gene for the tylosis esophageal cancer (TOC).
Although our previous studies showed familial aggrega-
tion of ESCC in Shanxi Province, China [35,36], no cases
with tylosis were identified in these high-risk families. In
the present study, decreased PPL mRNA expression was
significantly associated with a FH of UGI cancer. These
results suggest that additional examination of the rela-
tionship between members of the plakin family of genes,
particularly in familial ESCC, may be illuminating.
Table 3: mRNA expression of nine genes in ESCC patients
Gene Total 
number 
of cases
Distribution of N-fold mRNA expression No. (%) over-
expressed 
(N-fold ≥2.0)
No. (%) in 
"normal" 
expression 
range (N-fold 
range 0.5001–
1.9999)
No. (%) 
under-
expressed 
(N-fold ≤0.5)
N-fold 
change from 
previous 
cDNA array 
study 
(N = 19)**
Min 25th %5 0 th % 
(median)
75th %M a x
SPARC 75 0.1041 1.7695 4.4588 12.7286 91 53 (71%) 18 (24%) 4 (5%) 2.08
FADD 75 0.0055 1.5801 2.9897 6.4531 30 47 (63%) 25 (33%) 3 (4%) 2.04
Fascin 71* 0.0033 1.6896 5.1220 12.7878 1479 50 (70%) 10 (14%) 11 (15%) 2.22
COL7A1 75 0.0042 0.8746 3.0525 13.1775 285 43 (57%) 21 (28%) 11 (15%) 2.31
CK4 75 0.0000 0.0023 0.0206 0.1528 676 5 (7%) 8 (11%) 62 (83%) 0.16
TGM3 75 0.0000 0.0015 0.0209 0.3585 35858 6 (8%) 11 (15%) 58 (77%) 0.21
ECM1 75 0.0012 0.0159 0.0410 0.5236 140 7 (9%) 13 (17%) 55 (73%) 0.50
PPL 75 0.0076 0.0786 0.2306 0.8706 30 10 (13%) 15 (20%) 50 (67%) 0.41
EVPL 75 0.0040 0.0762 0.1856 0.9954 181 13 (17%) 12 (16%) 50 (67%) 0.48
*N = 71 as frozen tissue was exhausted
**Su et al, Cancer Res 2003;63:3872-6.BMC Cancer 2006, 6:33 http://www.biomedcentral.com/1471-2407/6/33
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There are no immediate clinical applications from the
findings reported here. Although our study size was only
modest, the lack of association with tumor characteristics
related to survival suggests that these nine genes are not
likely to be useful in predicting outcome or suggesting
specific therapies. Further evaluation of expression in rela-
tion to actual survival is needed to firm up this conclu-
sion, however. For the moment, the greatest clinical
potential for the nine genes studied here is their potential
as early detection markers.
Although the nine genes studied in present study were
well characterized at the mRNA level, changes at the pro-
tein level remain much less well characterized. Thus, logi-
cal next steps in future studies of these genes in ESCC are
to further correlate protein expression status with mRNA
expression, to evaluate the relation between protein
expression and tumor phenotype (ie, grade, differentia-
tion), to study the importance of cell location in protein
over-expression, and to assess the relation of each of these
factors to patient prognosis. In addition, we need to learn
when in the ESCC carcinogenesis process dysregulation
occurs if we are to determine the potential value of these
genes as biomarkers for the early detection of ESCC.
Conclusion
Results of the current study confirm that each of the nine
genes evaluated are significantly dysregulated in the
majority of ESCC cases and merit further investigation as
potential susceptibility and early detection markers.
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